Efficacy and safety of lodoxamide 0.1% vs cromolyn sodium 4% in patients with vernal keratoconjunctivitis

Am J Ophthalmol. 1992 Jun 15;113(6):632-7. doi: 10.1016/s0002-9394(14)74786-5.

Abstract

A multicenter, double-masked, parallel-group clinical study compared the efficacy and safety of lodoxamide 0.1% ophthalmic solution and cromolyn sodium 4% ophthalmic solution in 120 patients with vernal keratoconjunctivitis. On various follow-up visits, the clinical efficacy of lodoxamide 0.1% was statistically superior to cromolyn sodium 4% in alleviating four of the primary symptoms (itching, tearing, foreign-body sensation, and discomfort) and five of the primary signs (Trantas' dots, palpebral conjunctival changes, bulbar conjunctival hyperemia, erythema/swelling of the eyelids and periorbital tissues, and epithelial disease). At no time during the study was cromolyn sodium 4% statistically superior to lodoxamide 0.1% in demonstrating improvements in clinical signs and symptoms of vernal keratoconjunctivitis. The physician's clinical judgment of patients' response to treatment showed lodoxamide 0.1% effected a greater and earlier improvement than cromolyn sodium 4%. Both drugs were safe for topical ophthalmic use when used four times daily for up to 28 days.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Conjunctivitis, Allergic / drug therapy*
  • Cromolyn Sodium / adverse effects
  • Cromolyn Sodium / therapeutic use*
  • Double-Blind Method
  • Drug Tolerance
  • Eye Diseases / chemically induced
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Oxamic Acid / adverse effects
  • Oxamic Acid / analogs & derivatives*
  • Oxamic Acid / therapeutic use
  • Treatment Outcome

Substances

  • Cromolyn Sodium
  • Oxamic Acid
  • lodoxamide ethyl